Literature DB >> 6928985

Liposome-encapsulated methotrexate interactions with human chronic lymphocytic leukemia cells.

J A Todd, A M Levine, Z A Tökés.   

Abstract

The uptake of free and liposome-entrapped methotrexate (MTX) by human chronic lymphocytic leukemia cells was compared under incubation conditions resembling those encountered in vivo. Liposome encapsulation enhanced up to 200 times the association of MTX with these cells. Autoradiographic studies established an association of [3H]MTX liposomes with the cells. Such a mode of delivery did not significantly increase the amount of drug available to inhibit dihydrotolate dehydrogenase, which suggested that the liposome content was not readily available to the cytoplasmic sites of action. Increased doses of encapsulated MTX resulted in enzyme inhibitions that were similar to those obtained with the free drug. This finding demonstrates that higher doses of MTX delivered by liposomes could be potentially useful in overcoming drug-transport resistance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6928985

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery.

Authors:  Catriona McCallion; Anna D Peters; Andrew Booth; Karen Rees-Unwin; Julie Adams; Raisa Rahi; Alain Pluen; Claire V Hutchinson; Simon J Webb; John Burthem
Journal:  Blood Adv       Date:  2019-07-23

2.  Further studies on the charge-related alterations of methotrexate transport in Ehrlich ascites tumor cells by ionic liposomes: correlation with liposome-cell association.

Authors:  D W Fry; I D Goldman
Journal:  J Membr Biol       Date:  1982       Impact factor: 1.843

3.  Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).

Authors:  J Lautersztain; R Perez-Soler; A R Khokhar; R A Newman; G Lopez-Berestein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.

Authors:  Caterina Arru; Maria Rosaria De Miglio; Antonio Cossu; Maria Rosaria Muroni; Ciriaco Carru; Angelo Zinellu; Panagiotis Paliogiannis
Journal:  Adv Ther       Date:  2021-06-08       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.